Amarin names new senior vice president and head of development

Dr Soni joins Amarin from Pfizer where he held a number of leadership roles in Pfizer global R&D in both experimental medicine and late stage development.

Amarin has also announced its plans to locate its R&D headquarters in Connecticut, US. The new site, which is expected to be operational by end of 2008, will focus primarily on developing Amarin’s cardiovascular pipeline, including AMR101 which is entering Phase III for hypertriglyceridemia.

Thomas Lynch, chairman and CEO of Amarin, said: “Dr Soni’s appointment is an important milestone in the establishment of our new US R&D presence, which is being created to take advantage of our promising development opportunities in cardiovascular disease. This new location of our R&D headquarters will make it possible for us to attract talent from across the US.”